Surufatinib

Generic Name: Surufatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

Not Applicable

Conditions: Salivary Gland Carcinomas

Interventions: Drug: Surufatinib

First Posted Date: 2021-08-19

Last Posted Date: 2021-08-19

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 20

Registration Number: NCT05013515

Locations: 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Surufatinib
Drug: Surufatinib Plus Vinorelbine

First Posted Date: 2021-06-10

Last Posted Date: 2024-07-31

Lead Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Target Recruit Count: 60

Registration Number: NCT04922658

Locations: 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Phase 2

Conditions: Head and Neck Cancers - Salivary Gland

First Posted Date: 2021-06-02

Last Posted Date: 2021-06-02

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 27

Registration Number: NCT04910854

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Expanded Access Program of Surufatinib

Conditions: Neuroendocrine Tumors

First Posted Date: 2021-03-24

Last Posted Date: 2024-04-12

Lead Sponsor: Hutchmed

Registration Number: NCT04814732

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 8 locations

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Phase 2

Conditions: Advanced Colorectal Cancer

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-21

Last Posted Date: 2021-11-04

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 10

Registration Number: NCT04764006

Locations: 🇨🇳
China, Fujian, Fuzhou, Fujian, China

Surufatinib Hepatic Impairment Study

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-15

Last Posted Date: 2022-08-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 16

Registration Number: NCT04755075

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States

Surufatinib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-15

Last Posted Date: 2022-11-03

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 16

Registration Number: NCT04755088

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Surufatinib
Drug: Toripalimab
Drug: chemotherapy

First Posted Date: 2020-12-04

Last Posted Date: 2023-07-17

Lead Sponsor: Zhejiang University

Target Recruit Count: 61

Registration Number: NCT04653480

Locations: 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Open-Label Surufatinib in European Patients With NET

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Tumours
Neuroendocrine Tumour of the Lung
Small Intestinal NET

Interventions: Drug: Surufatinib

First Posted Date: 2020-10-08

Last Posted Date: 2024-02-09

Lead Sponsor: Hutchmed

Target Recruit Count: 78

Registration Number: NCT04579679

Locations: 🇫🇷
CHU Bordeaux, Pessac, France
🇺🇸
Stony Brook Cancer Center, Stony Brook, New York, United States
🇬🇧
Sarah Cannon Research Institute, London, United Kingdom

and more 20 locations

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Phase 2

Conditions: Thyroid Cancer

Interventions: Drug: Surufatinib
Drug: Toripalimab

First Posted Date: 2020-08-24

Last Posted Date: 2020-08-24

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT04524884

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy